Akeso, Inc.: Promising Financial Outlook and Strategic Advancements Drive Buy Rating

In a report released today, Jill Wu from CMB International Securities maintained a Buy rating on Akeso, Inc. (9926 – Research Report), with a price target of HK$102.61.

Jill Wu’s rating is based on Akeso, Inc.’s promising financial outlook and strategic advancements in their drug pipeline. The company demonstrated strong cost management in FY24, despite a revenue shortfall, and reported a significant year-over-year increase in product sales. Akeso’s robust cash reserves are expected to support ongoing research and development, as well as future commercial expansion.
Key factors contributing to the Buy rating include the potential of AK112 as a next-generation immuno-oncology therapy, with promising clinical trial results positioning it favorably against competitors. The inclusion of AK104 and AK112 in the National Reimbursement Drug List is anticipated to drive substantial sales growth in FY25. Additionally, Akeso’s strategic collaborations and expansion into new therapeutic areas through innovative drug combinations further bolster its growth prospects.

In another report released yesterday, CLSA also maintained a Buy rating on the stock with a HK$95.30 price target.